J. R. Wisniewski

A common druggable signature of oncogenic CMYC, mutant KRAS and mutant p53 reveals functional redundancy and competition of the oncogenes in cancer

Proteomics and phosphoproteomics profiling of the co-formulation of type I and II interferons, HeberFERON, in the glioblastoma-derived cell line U-87 MG

This study uses proteomic and phosphoproteomic analyses to investigate the effects of HeberFERON on U-87 MG glioblastoma cells, identifying key pathways and phosphosites involved in antiproliferative responses.

The response network of HSP70 defines vulnerabilities in cancer cells with the inhibited proteasome

The paper identifies HSP70 as a vulnerability in cancer cells under proteasome inhibition, showing its role in suppressing drug effects and linking its expression to patient risk.

Targeting of Protein Kinase CK2 in Acute Myeloid Leukemia Cells Using the Clinical-Grade Synthetic-Peptide CIGB-300

This study investigates the anti-proliferative and proapoptotic effects of the CK2 inhibitor CIGB-300 on AML cells and identifies its molecular targets.

Gel Electrophoresis/Electroelution Sorting Fractionator combined with Filter Aided Sample preparation (FASP) for deep proteomic analysis.

The paper introduces a new device for protein fractionation and demonstrates its effectiveness in increasing protein identification in proteomic analysis.

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945

This study examines the phosphoproteomic changes in AML cell lines treated with CX-4945, identifying key biological processes and pathways affected by CK2 inhibition.